Second, an indirect way through normalizing the tumor microenvironment, capmatinib-osimertinib combination regimen resulted in the reduced TGFβ1 secretion, which promotes CAF transformation, by the osimertinib-resistant NSCLC. Here, TGFB1 is linked to non-small cell lung carcinoma.